These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38138431)

  • 1. Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022.
    Gu M; Sun S; You Q; Wang L
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
    Gu J; Wu Q; Zhang Q; You Q; Wang L
    Eur J Med Chem; 2022 Dec; 243():114742. PubMed ID: 36155354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.
    Papapetropoulos A; Topouzis S; Alexander SPH; Cortese-Krott M; Kendall DA; Martemyanov KA; Mauro C; Nagercoil N; Panettieri RA; Patel HH; Schulz R; Stefanska B; Stephens GJ; Teixeira MM; Vergnolle N; Wang X; Ferdinandy P
    Br J Pharmacol; 2024 Jun; 181(11):1553-1575. PubMed ID: 38519837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2017 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2018 Aug; 23(8):1469-1473. PubMed ID: 29751111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.
    Bharate SS
    Drug Discov Today; 2021 Feb; 26(2):384-398. PubMed ID: 33221522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drug approvals for 2021: Synthesis and clinical applications.
    Yuan S; Wang DS; Liu H; Zhang SN; Yang WG; Lv M; Zhou YX; Zhang SY; Song J; Liu HM
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114898. PubMed ID: 36370552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of FDA-approved new molecular entities: 1827-2013.
    Kinch MS; Haynesworth A; Kinch SL; Hoyer D
    Drug Discov Today; 2014 Aug; 19(8):1033-9. PubMed ID: 24680947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability of comparative efficacy data at the time of drug approval in the United States.
    Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
    JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.
    Torre BG; Albericio F
    Molecules; 2017 Feb; 22(3):. PubMed ID: 28264468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook.
    Walter JR; Xu S
    Drug Discov Today; 2015 Nov; 20(11):1293-9. PubMed ID: 26116094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    G de la Torre B; Albericio F
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015.
    Lin HH; Zhang LL; Yan R; Lu JJ; Hu Y
    Sci Rep; 2017 Sep; 7(1):12230. PubMed ID: 28947756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2014 in review: FDA approval of new drugs.
    Kinch MS
    Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1619-1632. PubMed ID: 36951997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.